New cell therapy enters human testing for Tough-to-Treat blood cancer

NCT ID NCT05886491

Ongoing Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new cell therapy called GDX012 for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The main goals are to find out how safe the treatment is, what side effects patients experience, and to determine the best dose to use. The study will first test increasing doses in small groups, then expand to test the most promising doses in more patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, 60611, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
Sarah Cannon/CBCI

Denver, Colorado, 80218, United States
Thomas Jefferson University

New York, New York, 10065, United States
Tri-Star BMT/Sarah Cannon Nashville

Nashville, Tennessee, 37203, United States
University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, 35205, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

LEUKEMIA